PUMA

academical publication management
collect, organize, and share publications

( en | de )

 

Disambiguation of "Kontermann, Roland E."

Author of the publication

copydeleteadd this publication to your clipboard
Strategies for extended serum half-life of protein therapeutics

. Current Opinion in Biotechnology, 22 (6): 868--876 (2011)
DOI: 10.1016/j.copbio.2011.06.012

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Univ. -Prof. Dr. Roland Kontermann University of Stuttgart

E. Garrelts

E. Zafeiriou

Roland Weil University of Stuttgart

apl. Prof. Dr. Roland Gehrke University of Stuttgart

 

Other publications of authors with the same name

Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes., , , and . Methods in molecular biology (Clifton, N.J.), (2010)The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity, , , , , , and . Protein Engineering, Design and Selection, 25 (10): 603--612 (October 2012)A novel expression and purification system for the production of enzymatic and biologically active human granzyme B, , , , , , , and . Journal of Immunological Methods, 371 (1-2): 8--17 (2011)Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells, , , and . Journal of Drug Targeting, 15 (6): 399--406 (2007)Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity, , , , , , and . mAbs, (September 2018)Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma, , , , , , , , , and 1 other author(s). npj Systems Biology and Applications, 4 (1): 39 (December 2018)An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 \textlessi\textgreatertrans\textless/i\textgreater -Presentation at the Tumor Site, , , , and . Molecular Cancer Therapeutics, 11 (6): 1279--1288 (June 2012)Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma, , , , , , , , , and 16 other author(s). Clinical Cancer Research, (November 2018)Alternative antibody formats.. Current opinion in molecular therapeutics, 12 (2): 176--183 (2010)Systemic network analysis identifies XIAP and I kappa B alpha as potential drug targets in TRAIL resistant BRAF mutated melanoma, , , , , , , , , and 1 other author(s). NPJ systems biology and applications, (2018)